trending Market Intelligence /marketintelligence/en/news-insights/trending/YdRzKcFa_TWxXQlH9iPCZA2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Amicus Therapeutics raises $201M via underwritten common stock offering


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Amicus Therapeutics raises $201M via underwritten common stock offering

Amicus Therapeutics Inc. raised $201 million from an underwritten offering of common shares.

The Cranbury, N.J.-based company issued 18,720,930 shares at $10.75 apiece, which included the purchase of additional shares by underwriters.

Amicus Therapeutics plans to use the proceeds for the development of its expanded gene therapy pipeline and manufacturing capabilities for Pompe biologic AT-GAA and gene therapy product candidates.

The proceeds will also be used to complete the design and construction of the Amicus Process Science and Gene Therapy Manufacturing facility as well for general corporate and product development purposes.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC acted as joint book-running managers for the offering.